Open Access. Powered by Scholars. Published by Universities.®
Pharmacy and Pharmaceutical Sciences Commons™
Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Pharmacy and Pharmaceutical Sciences
Patients Living With Hiv Infection Are Less Likely To Receive The Correct Statin Intensity For Cardiovascular Disease Risk Reduction, Jason J. Schafer, Pharmd, Mph, Roshni Emmons, Pharmd, Bcps, Nick V. Hastain, Pharmd, Todd Miano, Pharmd, Phd
Patients Living With Hiv Infection Are Less Likely To Receive The Correct Statin Intensity For Cardiovascular Disease Risk Reduction, Jason J. Schafer, Pharmd, Mph, Roshni Emmons, Pharmd, Bcps, Nick V. Hastain, Pharmd, Todd Miano, Pharmd, Phd
College of Pharmacy Posters
- Patients living with HIV (PLWH) are at high risk for atherosclerotic cardiovascular disease (ASCVD)
- Eligible PLWH should receive statins for ASCVD risk reduction according to current guidelines
- Studies suggest that statins are underprescribed in PLWH, but comparisons to uninfected patients and assessments of statin intensity have not occurred
Objective
To determine the influence of HIV infection on appropriate statin prescribing for ASCVD risk reduction
Are Patients Living With Hiv Infection At Risk For Not Receiving Statin Medications For Cardiovascular Disease Risk Reduction?, Nick Hastain, Pharmd Candidate, Roshni S. Patel, Pharmd, Bcps, Jason J. Schafer, Pharmd, Mph, Bcps, Aahivp
Are Patients Living With Hiv Infection At Risk For Not Receiving Statin Medications For Cardiovascular Disease Risk Reduction?, Nick Hastain, Pharmd Candidate, Roshni S. Patel, Pharmd, Bcps, Jason J. Schafer, Pharmd, Mph, Bcps, Aahivp
College of Pharmacy Posters
Objective
To determine the prevalence of appropriate statin prescribing for ASCVD risk reduction in PLWH